Artificial cell therapy: New strategies for the therapeutic delivery of live bacteria

被引:55
作者
Prakash, S
Jones, ML
机构
[1] McGill Univ, Biomed Technol & Cell Therapy Res Lab, Dept Biomed Engn, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Fac Med, Artificial Cells & Organs Res Ctr, Montreal, PQ H3A 2B4, Canada
来源
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY | 2005年 / 01期
关键词
D O I
10.1155/JBB.2005.44
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
There has been rapid growth in research regarding the use of live bacterial cells for therapeutic purposes. The recognition that these cells can be genetically engineered to synthesize products that have therapeutic potential has generated considerable interest and excitement among clinicians and health professionals. It is expected that a wide range of disease modifying substrates such as enzymes, hormones, antibodies, vaccines, and other genetic products will be used successfully and will impact upon health care substantially. However, a major limitation in the use of these bacterial cells is the complexity of delivering them to the correct target tissues. Oral delivery of live cells, lyophilized cells, and immobilized cells has been attempted but with limited success. Primarily, this is because bacterial cells are incapable of surviving passage through the gastrointestinal tract. In many occasions, when given orally, these cells have been found to provoke immunogenic responses that are undesirable. Recent studies show that these problems can be overcome by delivering live bacterial cells, such as genetically engineered cells, using artificial cell microcapsules. This review summarizes recent advances in the therapeutic use of live bacterial cells for therapy, discusses the principles of using artificial cells for the oral delivery of bacterial cells, outlines methods for preparing suitable artificial cells for this purpose, addresses potentials and limitations for their application in therapy, and provides insight for the future direction of this emergent and highly prospective technology.
引用
收藏
页码:44 / 56
页数:13
相关论文
共 112 条
[31]   Preparation and stability of agarose microcapsules containing BCG [J].
Esquisabel, A ;
Hernández, RM ;
Igartua, M ;
Gascón, AR ;
Calvo, B ;
Pedraz, JL .
JOURNAL OF MICROENCAPSULATION, 2002, 19 (02) :237-244
[32]   Microencapsulation of L-acidophilus (La-05) and B-lactis (Bb-12) and evaluation of their survival at the pH values of the stomach and in bile [J].
Fávaro-Trindade, CS ;
Grosso, CRF .
JOURNAL OF MICROENCAPSULATION, 2002, 19 (04) :485-494
[33]   Survival of Ca-alginate microencapsulated Bifidobacterium spp. in milk and simulated gastrointestinal conditions [J].
Hansen, LT ;
Allan-Wojtas, PM ;
Jin, YL ;
Paulson, AT .
FOOD MICROBIOLOGY, 2002, 19 (01) :35-45
[34]   Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebinin(R), a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis [J].
Hida, M ;
Aiba, Y ;
Sawamura, S ;
Suzuki, N ;
Satoh, T ;
Koga, Y .
NEPHRON, 1996, 74 (02) :349-355
[35]  
Hilton, 1997, J Travel Med, V4, P41, DOI 10.1111/j.1708-8305.1997.tb00772.x
[36]  
Hirayama K, 1999, ANTON LEEUW INT J G, V76, P391
[37]   Oxalate-degrading Enterococcus faecalis [J].
Hokama, S ;
Honma, Y ;
Toma, C ;
Ogawa, Y .
MICROBIOLOGY AND IMMUNOLOGY, 2000, 44 (04) :235-240
[38]  
ISOLAURI E, 1991, PEDIATRICS, V88, P90
[39]  
JONES ML, IN PRESS APPL BIONIC
[40]   ENHANCEMENT OF THE CIRCULATING ANTIBODY SECRETING CELL RESPONSE IN HUMAN DIARRHEA BY A HUMAN LACTOBACILLUS STRAIN [J].
KAILA, M ;
ISOLAURI, E ;
SOPPI, E ;
VIRTANEN, E ;
LAINE, S ;
ARVILOMMI, H .
PEDIATRIC RESEARCH, 1992, 32 (02) :141-144